Indication
Myelodysplasia-Related
1 clinical trial
5 products
Clinical trial
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical TrialStatus: Recruiting, Estimated PCD: 2027-03-31
Product
AzacitidineProduct
CytarabineProduct
DaunorubicinProduct
Venetoclax